Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Galiximab"'
Publikováno v:
BioMed Research International, Vol 2021 (2021)
BioMed Research International
BioMed Research International
Minimal change disease (MCD) is the most common cause of idiopathic nephrotic syndrome in children, and it is well known for its multifactorial causes which are the manifestation of the disease. Proteinuria is an early consequence of podocyte injury
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2ea8e9a14e470f87285ca765fc4fd4
https://doaj.org/article/34cbbcf47a814b2ea8dc23fcecebbb4a
https://doaj.org/article/34cbbcf47a814b2ea8dc23fcecebbb4a
Autor:
Bruce D. Cheson, John C. Byrd, Myron S. Czuczman, Jeffrey L. Johnson, Sin-Ho Jung, Eric D. Hsi, John P. Leonard
Background This phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL). Patients and methods Patients with previously untreated FL (grades 1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed48eb92ce33bbbbf39de363d196fcc2
https://europepmc.org/articles/PMC6290880/
https://europepmc.org/articles/PMC6290880/
Autor:
Mario I. Vega, Benjamin Bonavida, Dana Clanton, Tracey Murphy, Lisa Berquist, Arturo Molina, Steffan Ho, Kandasamy Hariharan, Peter Chu
Publikováno v:
International Journal of Oncology
Galiximab is a primatized monoclonal antibody that targets CD80 expressed on malignant B cells and is being studied in the clinic as a potential treatment for follicular NHL. We have recently reported that galiximab signals B-NHL cells in vitro and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2901e1e42d27db6928a92ee3b5f2032f
https://doi.org/10.3892/ijo.2013.1986
https://doi.org/10.3892/ijo.2013.1986
Autor:
Bruce D. Cheson, Jeffrey L. Johnson, Sin-Ho Jung, Heiko Schöder, Nancy L. Bartlett, Sonali M. Smith
Publikováno v:
Leukemia & Lymphoma. 54:1405-1410
Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed–Sternberg cells. Gali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84808fc6cf83d78eaa378d010480975b
https://doi.org/10.3109/10428194.2012.744453
https://doi.org/10.3109/10428194.2012.744453
Autor:
Julie Ranuio, Randy D. Gascoyne, Naveen Dakappagari, Steffan N. Ho, Shabnam Tangri, Andrew P. Weng
Publikováno v:
Cytometry Part B: Clinical Cytometry. :112-119
Background: CD80 is a member of the B7 family of immune coregulatory proteins that mediate both immune activation and suppression. CD80 in particular has recently been shown to play an important role in supporting immune suppression through interacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30682c3be52fcec85afaf19e53e5ecb1
https://doi.org/10.1002/cyto.b.20631
https://doi.org/10.1002/cyto.b.20631
Autor:
Seema A. Bhat, Myron S. Czuczman
Publikováno v:
Expert Opinion on Biological Therapy. 10:451-458
A significant number of patients relapse or do not respond to rituximab due to intrinsic or acquired resistance. Hence, mAbs targeting other cell surface antigens on B-cell lymphomas are being studied. CD80 is a glycoprotein expressed on Hodgkin's ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8386e6bd8609e0e93bb47c804748fe4
https://doi.org/10.1517/14712591003596318
https://doi.org/10.1517/14712591003596318
Autor:
Mario I. Vega, Sara Huerta-Yepez, Stavroula Baritaki, Norio Uematsu, Ali R. Jazirehi, Loredana Militello, Demetrios A. Spandidos, Benjamin Bonavida
Publikováno v:
Forum on Immunopathological Diseases and Therapeutics. 1:81-95
A large number of hematologic malignancies of B-cell origin express the CD20 receptor on the cell surface. CD20 is expressed in the B-cell lineage and is absent in plasma cells. Antibodies directed against CD20 result in the elimination of normal and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0be4550667f2f858df2f12818925ec46
https://doi.org/10.1615/forumimmundisther.v1.i1-2.60
https://doi.org/10.1615/forumimmundisther.v1.i1-2.60
Publikováno v:
Clinical Lymphoma and Myeloma. 8:277-282
Monoclonal antibodies are expanding the therapeutic options for patients with B-cell lymphoma. Despite the antitumor activity of rituximab alone or in combination with systemic chemotherapy against various subtypes of B-cell lymphomas, a significant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c478aa13355c0dcbe10169df793a92a2
https://doi.org/10.3816/clm.2008.n.038
https://doi.org/10.3816/clm.2008.n.038
Autor:
John P. Leonard, Peter Martin
Publikováno v:
Clinical Lymphoma and Myeloma. 7:S192-S198
Non-Hodgkin lymphoma is a diverse group of lymphoid malignancies treated historically with cytotoxic chemotherapy. Recent technologic advances have enabled the development of new therapies specifically targeted to inhibit various pathways involved in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bedbfe9aed852e136f86f9fd3ad5996e
https://doi.org/10.3816/clm.2007.s.022
https://doi.org/10.3816/clm.2007.s.022
Publikováno v:
Seminars in Hematology. 44:S18-S21
Since its introduction 10 years ago, the anti-CD20 monoclonal antibody rituximab has benefited numerous patients with non-Hodgkin’s lymphoma (NHL). However, rituximab is not effective in all patients, and many patients who initially respond ultimat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d79c769ad4fe9604898597c175b1800
https://doi.org/10.1053/j.seminhematol.2007.06.005
https://doi.org/10.1053/j.seminhematol.2007.06.005